China Pharma Holdings (CPHI) Non-Current Debt (2013 - 2025)

China Pharma Holdings (CPHI) has reported Non-Current Debt for 13 consecutive years, with $1.3 million the latest figure, recorded in Q2 2025.

• For the quarter ending Q2 2025, Non-Current Debt fell 5.93% year-over-year to $1.3 million; the trailing twelve-month figure through Jun 2025 stood at $1.3 million (down 5.93% YoY), and the FY2024 full-year result was $1.4 million, down 1.47% from the prior year.
• Non-Current Debt fell to $1.3 million in Q2 2025 per CPHI's latest filing, from $1.4 million in the prior quarter.
• Across five years, Non-Current Debt topped out at $1.5 million in Q3 2022 and bottomed at $325072.0 in Q2 2021.
• Historically, Non-Current Debt has averaged $1.2 million across 5 years, with a median of $1.4 million in 2023.
• The sharpest annual moves came in 2021 and 2022: Non-Current Debt tumbled 83.56% in 2021, then surged 92.5% in 2022.
• Over 5 years, Non-Current Debt stood at $1.2 million in 2021, then jumped by 30.6% to $1.5 million in 2022, then decreased by 8.32% to $1.4 million in 2023, then dropped by 1.47% to $1.4 million in 2024, then retreated by 5.12% to $1.3 million in 2025.
• According to Business Quant data, Non-Current Debt over the past three periods registered $1.3 million, $1.4 million, and $1.4 million for Q2 2025, Q1 2025, and Q4 2024 respectively.